Navigation Links
bite in Biological Technology

Micromet Closes $80.5 Million Public Offering of Common Stock

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... from the European Medicines Agency (EMEA) for bite antibody blinatumomab (MT103) for acute ... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ...

Micromet Announces Pricing of Public Offering of Common Stock

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet Announces Public Offering of Common Stock

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet Added to Russell 3000 Index

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... as well as conventional monoclonal antibodies. bite antibodies represent a new class of antibodies ... antibodies are currently in clinical trials. Its bite antibody blinatumomab (MT103) is in a phase 2 ... with non-Hodgkin's lymphoma (NHL). A second bite antibody, MT110, is in a phase 1 clinical trial ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... with non-Hodgkin's lymphoma. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... with non-Hodgkin's lymphoma. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

... with lung or gastrointestinal cancer. bite antibodies such as MT110 represent a novel class ... (3). The data presented at AACR show that the bite antibody MT110 can direct T cells to eliminate ... from a study of MT110 in mice showed that the bite antibody eliminated even large numbers of ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... demonstrating the potent anti-tumor activity of a bite antibody binding to carcinoembryonic antigen ... as target antigen for development of a new bite antibody program because CEA is widely expressed ... antibody efficacy. The new study shows that novel bite antibodies have strong activity against ...

Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... with non-Hodgkin's lymphoma. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

... of Sir Walter Bodmer and Bernard Fox to its bite antibody advisory panel. Other members of the ... in key areas relevant for the development of new bite antibodies for the treatment of cancer." ... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ...

Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research

... human colon cancer cells by T cell-engaging bite antibodies derived from anti-EGFR antibodies ... colon cancer stem cells by EpCAM/CD3-bispecific bite antibody MT110. AACR Annual Meeting 2009, ... redirected target cell lysis by T cell-engaging bite antibody MT110. AACR Annual Meeting 2009, ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... the rights in North America to its most advanced bite antibody candidate, blinatumomab, also known as ... a research program for the development of a new bite antibody for the treatment of hematological ... excited about the prospects for 2009. Our lead bite antibody program blinatumomab reported ...

Micromet to Present at the Cowen Health Care Conference on March 17, 2009

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors

... candidates to pivotal trials." "Micromet's bite antibodies have the potential to become the next ... and contributing to the development of its bite antibodies and other clinical stage product ... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ...

Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009

... antibody technology is based on its proprietary bite antibody platform, representing a new class of ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... option to Bayer Schering Pharma AG to license a bite antibody against an undisclosed solid tumor ...

Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling

... binding to EpCAM. MT110, an EpCAM-specific bite antibody, is being tested in a phase 1 clinical ... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ...

Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG

... obtain a license to one of Micromet's preclinical bite antibodies against an undisclosed oncology ... to secure a one year option on a specific bite antibody. Bayer Schering Pharma may exercise ... Bayer Schering Pharma on the development of the bite antibody through the completion of phase 1 ...

Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

... 2 clinical trial of blinatumomab for ALL find the bite antibody was able to eliminate MRD. Six patients ... passcode: 39298646. About bite Antibodies BiTE(R) antibodies are ... to escape recognition by T cells. The use of bite antibodies that are specifically designed to ...

Micromet to Present at the RBC Capital Markets Healthcare Conference

... development. The Company's lead program is a bite antibody known as blinatumomab, or MT103. It is ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... psoriasis, or multiple sclerosis. Additional bite antibodies, targeting CEA, CD33, Her2, EGFR and ...

Micromet Added to NASDAQ Biotechnology Index

... antibody technology is based on its proprietary bite antibody platform, representing a new class of ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... psoriasis, or multiple sclerosis. Additional bite antibodies, targeting CEA, CD33, Her2, EGFR and ...

Micromet, Inc. Reports Third Quarter 2008 Financial Results

... antibody technology is based on its proprietary bite antibody platform, representing a new class of ... subsidiary of AstraZeneca plc. Micromet's second bite antibody in clinical development is MT110, which ... psoriasis, or multiple sclerosis. Additional bite antibodies, targeting CEA, CD33, Her2, EGFR and ...

Micromet Closes $40 Million Private Equity Placement

... R&D Efforts and Clinical Trials Advancing the bite Therapeutic Antibody Platform BETHESDA, Md., ... our clinical antibody programs and to broaden our bite antibody pipeline." Under the terms of the ... of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies ...

Micromet Announces Definitive Agreement for $40 Million Private Equity Placement

... R&D Efforts and Clinical Trials Advancing the bite Therapeutic Antibody Platform BETHESDA, Md., ... of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies ... of our product candidates, the development of our bite antibody technology, the conduct, timing and ...

Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule

... of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies ... of AstraZeneca plc. MT110 is the second bite antibody in clinical trials, and is being ... of our product candidates, the development of our bite antibody technology, the conduct, timing and ...

Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer

... of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies ... of AstraZeneca plc. MT110 is the second bite antibody in clinical trials, and is being ... of our product candidates, the development of our bite antibody technology, the conduct, timing and ...

Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results

... in late stage lymphoma patients. The bite antibody could also clear the bone marrow and ... completed preclinical development for its second bite antibody MT110. MT110 binds to EpCAM, a cell ... 2007, we have made significant progress with our bite antibodies demonstrating strong clinical ...

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference

... Presentation on MCSP-specific bite Antibody Selected by AACR for Press ... target biology and therapeutic window for two new bite antibodies in pre-clinical development. bite antibodies are T cell recruiting antibodies ...

Scientists say sabercat bit like a pussycat

... called Finite Element Analysis (FEA) to test the bite force and feeding mechanics of the fearsome ... More recently, people have suggested that the bite was strong." Using the skull of a modern-day ... determined that Smilodon had a relatively weak bite - about one third as powerful as a lion of ...

Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results

... clinical trial for the treatment of patients with non-Hodgkin's lymphoma. bite antibodies represent a new class of antibodies that activate a patient's ... and intended utilization of our product candidates, the development of our bite antibody technology, the conduct, timing and results of future clinical ...

Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine

... About China's Veterinary Rabies Vaccine Market Rabies is a fatal infection of the central nervous system acquired through the bite of a rabid animal. The fatality rate of this infection is 100% when left untreated. The World Health Organization (WHO) recognizes rabies as ...

IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis

... has caused epidemics in India, Africa, Latin America and along the Mediterranean coast. Leishmania parasites are transmitted to humans through the bite of infected sandflies. Visceral leishmaniasis, the most severe form of the disease, causes fatal infections of internal organs, while the cutaneous ...

New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS

... them from re-circulating. Atrium formed a partnership with the University of Aberdeen and Rothamsted Research, who, having discovered why midges bite some people and not others, developed a more effective midge repellent naturally produced by humans. When looking for an efficient spray technology ...

Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations

... (UK) +44(0)207-831-3113 edward.bridges@fd.com Tania Kempf Cohn & Wolfe (US) +1-650-281-7556 Tania_Kempf@sfo.cohnwolfe.com Clare Gayner bite Communications (UK) +44(0)20-8834-3454 Clare.Gayner@bitepr.com ...

Insulet Reports First Quarter 2008 Results

... Inc. and presented at the American Association for Cancer Research meeting in April exploring different routes of administration of its bite antibody MT110 for the treatment of cancer. * Insulet is an industry partner in a majority of the sites supporting the Juvenile Diabetes ...

MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research

... 8:00 a.m. - 12:00 p.m. in Exhibit Hall B-F. -- Bioavailability, Pharmacodynamic Activity, and Anti-Tumor Efficacy of the CD19/CD3-Specific bite Antibody MEDI-538 (MT103) Delivered Subcutaneously in Animal Models (Poster Session: Antibodies and Immunotherapy, abstract 2131, poster ...

AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights

... are liposomal amphotericin (Ambisome(R)) and Paromomycin. About leishmaniasis Leishmaniasis is an infectious disease transmitted by the bite of the phlebotomine sandfly. The cutaneous form of the disease normally produces skin ulcers on the exposed parts of the body such as the face, arms ...
Other Contents
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... to Wednesday, Oct. 18-22, 2014 , WHERE: ... Drive, San Diego, CA 92101 , WHAT: ... presentations of the latest research in human genetics. ... featuring high-scoring abstracts on rare genetic variants in ... and treatment for sun sensitivity (Saturday, Oct. 18, ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- People who use ... the lower levels of nicotine, according to a new ... chemicals than other smokers, the researchers say. The ... 65, who smoked regular cigarettes with nicotine emission levels ... participants then switched to reduced-nicotine cigarettes for the next ...
(Date:8/22/2014)... News) -- Many children get anxious or afraid when ... a number of ways that parents can make these ... The first step is to explain to children in ... health, said Rita John, director of the pediatric primary ... Nursing in New York City. "Children need to ...
(Date:8/22/2014)... (HealthDay News) -- College can be a challenging time for ... can do to make the most of their new life, ... explore, meet new people and learn to manage the temptations ... and assessment at St. John,s University in New York City, ... takes place in the classroom. College is a time when ...
(Date:8/22/2014)... A new, online conference is coming August ... is no-cost and open to everyone. Over 20 top ... and advice on how to stop emotional eating, start eating ... Mindful eating is not a diet. The concept is about ... an "eat this, don't eat that" approach. , You can ...
(Date:8/22/2014)... surgery for facial pain caused by trigeminal neuralgia, the ... a study in the September issue of ... of Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , Percutaneous stereotaxic rhizotomy ... than other types of surgical treatments for trigeminal neuralgia, ...
Breaking Medicine News(10 mins):Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2Health News:College Prep 101 2Health News:20 Top Experts Discuss How to Unravel the Food-Mood Connection 2Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2
Other TagsOther Tags